Walker AM. Common language. Pharmacoepidemiology and Drug Safety, 1996; 5:415-418.

Walker AM. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arth Rheum, 1997; 40: 201-208.

Walker AM, Szneke P, Bianchi L, Field LG, Sutherland LR, Dreyer NA. 5-Aminosalicylates, sulfasalazine, steriod use, and complications in patients with ulcerative colitis. Am J Gastroenterol, 1997; 92: 816-820.

Waler AM, Funch DP, Bianchi L, and Blot WJ. Shop order fracture rate as a risk factor for strut fracture in Bjork-Shiley CC60 degree heart valves. J Heart Valve Dis, 1997; 6:264-267.

Andrade SE, Walker AM, Platt R, Hollenberg NK, Testa MA, Saperia GM, and Gottlieb LK. Discontinuation of antihyperlipidemic drugs: Do rates reported in clinical trials predict rates in primary care settings? N Engl J Med, 1995; 332:1125-1131.

Walker AM, Lanza LL, Arellano F, and Rothman KJ. Mortality in current and former users of clozapine. Epidemiology, 1997; 8:1-7.

Walker AM. Low power and striking results – A surprise but not a paradox (editorial). N Engl J Med, 1995; 332:1091-1092.

Oliveria SA, Felson DT, Reed JI, Cirillo PA, and Walker AM. The incidence of symptomatic hand, hip and knee osteoarthritis in a health maintenance organization. Arthritis Rheum, 1995; 38:1134-1141.

Chan KW, Walker AM, Yood RA. An equilibrium model of drug utilization. J Clin Epidemiol, 1993; 46:113-121.

Gray DT, Fyler DC, Walker AM, Weinstein MC, and Chalmers TC. Clinical outcomes and cost of transcatheter vs. surgical closure of patent ductus arteriosus. N Engl J Med, 1993; 329:1517-1523.